There is 1 paper on postprandial SPARC in aging research: 1 trial in people.
1 paper studies it7 findings
See all 1 papers on postprandial SPARC
“individuals with higher baseline SPARC-1H levels were associated with fewer improvements in fasting insulin (β ± SE: 1.54 ± 0.43; P = 0.002), fasting glucose (0.10 ± 0.04; P = 0.049), the homeostasis model assessment of insulin resistance (HOMA-IR, 0.47 ± 0.12; P = 0.0005)”
- Human trial1
Interventions
1Mediterranean diet
downin humans1
1 study
Mediterranean diet
downin humans1
Mediterranean diet decreases postprandial SPARC in humans after 6-month calorie restriction.
“Intriguingly, only in the MD group, plasma SPARC-1H levels decreased significantly after 3-month (P = 0.009) and 6-month (P = 0.028) CR, while no significant changes of SPARC-1H levels were found in the TJD or CD group.”
Human trialafter 6-month calorie restriction6 monthsn = 81
Life metabolism
Associations
3Fasting glucose
upin humans1
1 study
Fasting glucose
upin humans1
Postprandial SPARC predicts fasting glucose in the Mediterranean diet group from baseline to 6 months.
“baseline SPARC-1H levels were positively associated with the changes in HOMA-IR (P = 0.0005), HOMA-β (P = 0.047), fasting insulin (P = 0.002), and fasting glucose (P = 0.049) from baseline to 6 months, specifically in the MD group”
Human trialin the Mediterranean diet group from baseline to 6 months6 monthsn = 81
Life metabolism
Postprandial SPARC predicts fasting glucose in Mediterranean diet group (β = 0.10 ± 0.04, P = 0.049).
“fasting glucose (0.10 ± 0.04; P = 0.049)”
Human trialin Mediterranean diet groupplasma6 months
Life metabolism
Fasting insulin
upin humans1
1 study
Fasting insulin
upin humans1
Postprandial SPARC predicts fasting insulin in the Mediterranean diet group from baseline to 6 months.
“baseline SPARC-1H levels were positively associated with the changes in HOMA-IR (P = 0.0005), HOMA-β (P = 0.047), fasting insulin (P = 0.002), and fasting glucose (P = 0.049) from baseline to 6 months, specifically in the MD group”
Human trialin the Mediterranean diet group from baseline to 6 months6 monthsn = 81
Life metabolism
Postprandial SPARC predicts fasting insulin in Mediterranean diet group (β = 1.54 ± 0.43, P = 0.002).
“individuals with higher baseline SPARC-1H levels were associated with fewer improvements in fasting insulin (β ± SE: 1.54 ± 0.43; P = 0.002)”
Human trialin Mediterranean diet groupplasma6 months
Life metabolism
HOMA-IR
upin humans1
1 study
HOMA-IR
upin humans1
Postprandial SPARC predicts HOMA-IR in the Mediterranean diet group from baseline to 6 months.
“baseline SPARC-1H levels were positively associated with the changes in HOMA-IR (P = 0.0005), HOMA-β (P = 0.047), fasting insulin (P = 0.002), and fasting glucose (P = 0.049) from baseline to 6 months, specifically in the MD group”
Human trialin the Mediterranean diet group from baseline to 6 months6 monthsn = 81
Life metabolism
Postprandial SPARC predicts HOMA-IR in Mediterranean diet group (β = 0.47 ± 0.12, P = 0.0005).
“individuals with higher baseline SPARC-1H levels were associated with fewer improvements in fasting insulin (β ± SE: 1.54 ± 0.43; P = 0.002), fasting glucose (0.10 ± 0.04; P = 0.049), the homeostasis model assessment of insulin resistance (HOMA-IR, 0.47 ± 0.12; P = 0.0005)”
Human trialin Mediterranean diet groupplasma6 months
Life metabolism